Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy
Authors:
- Neil G BurnetNBNeil G Burnet
- Thomas MeeTMThomas Mee
- Simona GaitoSGSimona Gaito
- Norman F KirkbyNKNorman F Kirkby
- Adam H AitkenheadAAAdam H Aitkenhead
- Carmel N AnandadasCACarmel N Anandadas
- Marianne C AznarMAMarianne C Aznar
- Lisa H BarracloughLBLisa H Barraclough
- Gerben BorstGBGerben Borst
- Frances C CharlwoodFCFrances C Charlwood
- Matthew ClarkeMCMatthew Clarke
- Rovel J ColacoRCRovel J Colaco
Open Access
- 1 May 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1133) , 20211175
Abstract
Objectives: High-energy Proton Beam Therapy (PBT) commenced in England in 2018 and NHS England commissions PBT for 1.5% of patients receiving radical radiotherapy. We sought expert opinion on the level of provision. Methods: Invitations were sent to 41 colleagues working in PBT, most at one UK centre, to contribute by completing a spreadsheet. 39 responded: 23 (59%) completed the spreadsheet; 16 (41%) declined, arguing that clinical outcome data are lacking, but joined six additional site-specialist oncologists for two consensus meetings. The spreadsheet was pre-populated with incidence data from Cancer Research UK and radiotherapy use data from the National Cancer Registration and Analysis Service. ‘Mechanisms of Benefit’ of reduced growth impairment, reduced toxicity, dose escalation and reduced second cancer risk were examined. Results: The most reliable figure for percentage of radical radiotherapy patients likely to benefit from PBT was that agreed by 95% of the 23 respondents at 4.3%, slightly larger than current provision. The median was 15% (range 4–92%) and consensus median 13%. The biggest estimated potential benefit was from reducing toxicity, median benefit to 15% (range 4–92%), followed by dose escalation median 3% (range 0 to 47%); consensus values were 12 and 3%. Reduced growth impairment and reduced second cancer risk were calculated to benefit 0.5% and 0.1%. Conclusions: The most secure estimate of percentage benefit was 4.3% but insufficient clinical outcome data exist for confident estimates. The study supports the NHS approach of using the evidence base and developing it through randomised trials, non-randomised studies and outcomes tracking. Advances in knowledge: Less is known about the percentage of patients who may benefit from PBT than is generally acknowledged. Expert opinion varies widely. Insufficient clinical outcome data exist to provide robust estimates. Considerable further work is needed to address this, including international collaboration; much is already underway but will take time to provide mature data.Keywords
This publication has 59 references indexed in Scilit:
- Rectal Toxicity After Proton Therapy For Prostate Cancer: An Analysis of Outcomes of Prospective Studies Conducted at the University of Florida Proton Therapy InstituteInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Position statement on ethics, equipoise and research on charged particle radiation therapyJournal of Medical Ethics, 2013
- Proton Therapy for Skull Base Chordomas: An Outcome Study from the University of Florida Proton Therapy InstituteJournal of Neurological Surgery Part B: Skull Base, 2013
- Methodological Considerations in the Evaluation of Radiotherapy TechnologiesClinical Oncology, 2012
- Charged particles in radiotherapy: A 5-year update of a systematic reviewRadiotherapy and Oncology, 2012
- Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09Journal of Clinical Oncology, 2010
- De testimonio: on the evidence for decisions about the use of therapeutic interventionsThe Lancet, 2008
- Should Randomized Clinical Trials Be Required for Proton Radiotherapy?Journal of Clinical Oncology, 2008
- Proton Therapy in Clinical Practice: Current Clinical EvidenceJournal of Clinical Oncology, 2007
- Number of patients potentially eligible for proton therapyActa Oncologica, 2005